• About us
• Contact

Advertisement

Person › Details

Jason Loveridge (4SC AG (FSE: VSC))

Loveridge, Jason (4SC 201609– CEO)

 

	Organisation	4SC AG (FSE: VSC)
	Group	4SC (Group)
	Product	domatinostat (4SC-202)
	Product 2	drug development

Record changed: 2023-10-31

Advertisement

More documents for Jason Loveridge

• [1] 4SC AG. (10/18/23). "Press Release: 4SC Receives Orphan Drug Designation (ODD) for Resminostat (Kinselby) in CTCL in the European Union". Planegg-Martinsried....
• [2] 4SC AG. (9/27/23). "Press Release: 4SC Receives Orphan Drug Designation (ODD) for Resminostat (Kinselby) in CTCL from the US FDA". Planegg-Martinsried....
• [3] Immunic, Inc.. (3/31/21). "Press Release: Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838". New York, NY & Planegg-Martinsried....
• [4] 4SC AG. (11/25/20). "Press Release: 4SC AG Resolves to Issue New Shares with Expected Proceeds of approx. EUR 7.5 Million (ad hoc) [not for US, AU, CA, JP, ZA, et al.]". Planegg-Martinsried....
• [5] 4SC AG. (9/11/20). "Press Release: 4SC and Maruho Discontinue Collaboration for Development of 4SC’s Kv1.3 Inhibitors". Planegg-Martinsried....
• [6] 4SC AG. (10/7/19). "Press Release: 4SC AG Resolves to Issue New Shares, Santo and ATS Undertake to Subscribe / Buy the New Shares [Not for US, AU, CA, et al.]". Planegg-Martinsried....
• [7] 4SC AG. (3/20/19). "Press Release: 4SC AG Provides Results for Financial Year 2018 and Outlook". Planegg-Martinsried....
• [8] 4SC AG. (2/6/19). "Press Release: First Patient Enrolled in Phase II Study EMERGE of Domatinostat (4SC-202) in Gastrointestinal Cancer". Planegg-Martinsried....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.